Pyxis Oncology, Inc. (PYXS): Total Liabilities
$38.11M
As of 2025-12-31
$43.48M
As of 2026-06-30
-9.0%
3-year compound annual growth
+58.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.11M | +4.6% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $36.43M | -24.1% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $48.02M | -5.0% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $50.55M | +170.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $18.71M | +385.4% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $3.85M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $5.49M | -10.4% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $34.90M | +208.9% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $1.84M | -77.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $32.02M | +37.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $19.38M | -32.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
Compare PYXS, CVSI, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗